Find Clinical Trials

Advanced Search

Study phase

Document

Therapeutic area group

Indication

SEARCH CLEAR

185 Results

Protocol Code Study Title Active substance/Medical device Study Phase Therapeutic Area
CL2-18886-026 Effects of terutroban versus aspirin on composition of atherosclerotic plaque in patients undergoing a carotid… TERUTROBAN,
S018886 		Phase 2 Cardiovascular Diseases
CL2-16257-101 Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients… IVABRADINE,
S016257 		Phase 2 Cardiovascular Diseases
CL2-16257-099 Effects of ivabradine on vascular function in individuals at increased risk of developing cardiovascular disease… IVABRADINE,
S016257 		Phase 2 Cardiovascular Diseases
CL2-16257-096 Effects of oral chronic administration of ivabradine (7.5 mg bid) in comparison to placebo (bid)… IVABRADINE,
S016257 		Phase 2 Cardiovascular Diseases
CL2-16257-095 Effects of oral administration of ivabradine (7.5 mg bid) on post-ischaemic stunning induced by exercise… IVABRADINE,
S016257 		Phase 2 Cardiovascular Diseases
CL2-16257-090 Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy… IVABRADINE,
S016257 		Phase 2 Cardiovascular Diseases
CL2-16257-088 Effects of ivabradine IV versus placebo on haemodynamic parameters in patients with a low cardiac… IVABRADINE,
S016257 		Phase 2 Cardiovascular Diseases
CL2-16257-073 Evaluation of the effects of oral administration of ivabradine 5 mg and 7.5 mg b.i.d.… IVABRADINE,
S016257 		Phase 2 Cardiovascular Diseases
CL2-16257-062 Evaluation of the effects of 3 successive oral dosages (2.5; 5; 7.5 mg b.i.d.) of… IVABRADINE,
S016257 		Phase 2 Cardiovascular Diseases
CL2-16257-060 Evaluation of the effects on heart rate, haemodynamic parameters, safety and tolerability of 5 mg… IVABRADINE,
S016257 		Phase 2 Cardiovascular Diseases
CL2-16257-053 Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure IVABRADINE,
S016257 		Phase 2 Cardiovascular Diseases
CL2-12911-039 A double-blind, multicenter, international randomised study to assess the effects of 4 month-oral administration of… STRONTIUM RANELATE,
S012911 		Phase 2 Rheumatology
CL2-09490-157 Assessment of the effects on 24-hour ambulatory blood pressure and the safety of a once-a-day… PERINDOPRIL TERT BUTYLAMINE,
S009490 		Phase 2 Cardiovascular Diseases
CL2-066913-002 A randomized, double blind, placebo-controlled, parallel, international multicenter study assessing the efficacy of S066913 in… S066913 Phase 2 Cardiovascular Diseases
CL2-05985-005 Efficacy and safety of the fixed oral low-dose perindopril arginine 3.5 mg/amlodipine 2.5 mg combination… AMLODIPINE, PERINDOPRIL ARGININE,
S005985 		Phase 2 Cardiovascular Diseases
CL2-05720-005 Efficacy and safety assessment of two schemes of oral administration of once-daily extended release metformin… GLICLAZIDE, METFORMINE,
S005720 		Phase 2 Metabolism
CL2-05682-102 Impact of Daflon 500 mg on the progression of chronic venous disease and symptoms in… MICRONISED PURIFIED FLAVONOID FRACTION,
S005682 		Phase 2 Cardiovascular Diseases
CL2-05682-099 Effects of micronised purified flavonoic fraction on microcirculation in women suffering from chronic venous disease MICRONISED PURIFIED FLAVONOID FRACTION,
S005682 		Phase 2 Cardiovascular Diseases
CL1-95005-001 Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer TIPIRACIL, TRIFLURIDINE,
S095005 		Phase 1 Cancers
CL1-81694-001 Phase I dose-escalation study of S 81694 administered intravenously in adult patients with advanced/metastatic solid… S081694 Phase 1 Cancers
CL1-80881-007 An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy,… LUCITANIB,
S080881 		Phase 1-2 Cancers
CL1-78454-009 Phase I dose escalation study of oral administration of Pan-Histone Deacetylase (HDAC) inhibitor S 78454… ABEXINOSTAT,
S078454 		Phase 1 Cancers
CL1-78454-008 Phase I dose-escalation study of oral administration of the Histone Deacetylase (HDAC) Inhibitor S 78454… ABEXINOSTAT,
S078454 		Phase 1 Cancers
CL1-78454-006 Phase I dose-escalation study of S 78454 (HDACi) p.o. in combination with FOLFOX in patients… ABEXINOSTAT,
S078454 		Phase 1 Cancers
CL1-78454-005 Phase I dose-escalation study of oral administration of S 78454 given with a fixed dose… ABEXINOSTAT,
S078454 		Phase 1 Cancers

Servier clinical trials are mainly registered on


EU Clinical Trials Register

The EU Clinical Trials Register contains information on interventional clinical trials on medicines conducted in Europe, which started after 1 May 2004.

SEE MORE

ClinicalTrials.gov

Clinicaltrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.

SEE MORE

ISRCTN registry

The ISRCTN registry is a primary clinical trial registry recognised by WHO and ICMJE that accepts all clinical research studies.

SEE MORE
© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility